



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application

Inventor(s): Peter D. Gluckman, Jian Guan, Tajrena Alexi

Appln. No.: 10/606,574

Confirm. No.: 4791

Filed: June 26, 2003

Title: REGULATION OF TYROSINE HYDROXYLASE  
BY GPE

PATENT APPLICATION

Art Unit:

Examiner:

Customer No. 23910

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8**

I hereby certify that this correspondence is being deposited in the United States Postal Service with sufficient postage as first class mail in an envelope addressed to **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**, on March 17, 2004

(Attorney Signature)

D. Benjamin Borson, Reg. No. 42,349

Signature Date: March 17, 2004

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

It is requested that the information identified in this statement be considered by the Examiner and made of record in the above-identified application. This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56. If this is a continuation, divisional or continuation-in-part application, it is understood that the Examiner will consider all information which was considered by the Office in a parent application. MPEP §609. Such information therefore is not listed herein unless it is desired that the information be printed on a patent issuing from the subject application.

***Enclosed with this statement are the following:***

- ☒ Form PTO-1449. The Examiner is requested to initial the form and return it to the undersigned in accordance with M.P.E.P. §609.

This statement qualifies under 37 C.F.R. §1.97, subsection (b) because:

- (1) It is being filed within three months of the filing date of an application other than a continued prosecution application under § 1.53(d);  
-- OR --
- (2) It is being filed within 3 months of entry of a national stage;

-- OR --

- (3) It is being filed before the mailing date of the first Office Action on the merits,  
-- OR --  
(4) It is being filed before the mailing date of the first Office Action after the filing of  
a Request for Continued Examination under 37 C.F.R. §1.114.

✓ **Fee Authorization.** The Commissioner is hereby authorized to charge any deficiencies or credit any overpayment to Deposit Account No. 06-1325. A duplicate copy of this authorization is enclosed.

Respectfully submitted,


FLIESLER MEYER LLP

Date: March 18, 2004

By: \_\_\_\_\_

D. Benjamin Borison  
Reg. No. 42,349

FLIESLER MEYER LLP  
Four Embarcadero Center, Fourth Floor  
San Francisco, California 94111-4156  
Telephone (415) 362-3800



Form PTO-1449  
(Substitute)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

Attorney Docket Number  
NRNZ-1005US1

Application Number  
10/606,574

*Information Disclosure Statement*  
**BY APPLICANT**  
(Use several sheets if necessary)

Applicant Owner: Gluckman et al.

Filing Date: June 26, 2003

**U.S. PATENTS**

Examiner Initial	Patent Number	Issue Date	First Named Inventor			
	6,294,585	9/25/01	Brown			
	6,187,906	2/13/01	Gluckman, et al.			
	5,714,460	2/3/98	Gluckman, et al.			

**U.S. PATENT PUBLICATIONS**

Examiner Initial	Application Number	Filing Date	First Named Inventor		
	2002/0035066 A1	5/24/01	Gluckman		

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
	WO 98/14202	4/9/98	PCT			
	0 366 638 A2	2/5/90	EP0			
	WO 95/17204	6/29/95	PCT			

**OTHER DOCUMENTS** (Include author (if any), title, publisher and place of publication, date and pertinent pages)

	Sara, Vicki R., et. al., "The Biological Role of Truncated Insulin-like Growth Factor-1 and the Tripeptide GPE in the Central Nervous System", Annals of the New York Academy of Sciences, 692, 1993, 183-191
	Sara, Vicki R., et. al., "Identification of Gly-Pro-Glu (GPE), the Aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide", Biochemical and Biophysical Research Communications, Vol. 165. No. 2, December 15, 1989, 766-771
	Saura, J., et. al., "Neuroprotective effects of Gly-Pro-Glu, the N-terminal tripeptide of IGF-1, in the hippocampus in vitro", NeuroReport, Vol. 10, No. 1, January 1999, 161-164
	Nilsson-Hakansson, Lena, et. al., "Effects of IGF-1, truncated IGF-1 and the tripeptide Gly-Pro-Glu on acetylcholine release from parietal cortex of rat brain", NeuroReport, Vol. 4, No. 9, August 1993 (September Issue), 1111-1114

OTHER DOCUMENTS (Include author (if any), title, publisher and place of publication, date and pertinent pages)		
		Ludecke et al., "Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by point mutation (L205P) in the tyrosine hydrolyse gene", Hum. Gen. 102:644-646 (1998)
		Danks et al., "Tetrahydrobiopterin treatment of variant form of phenylketonuria", Lancet 2:1043, 1975
		Ludecke et al., "A point mutation in the tyrosine hydroxylase gene associated with Segawa's syndrome", Hum. Gen. 93:123 (1995)
		Mallet, "Tyrosine hydroxylase from cloning to neuropsychiatric disorders", Brain Research Bulletin 50(5,6):381-382 (1999).
		Guan et al., "N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats", Brain research 2000, Mar 24 859(2), 286-92.
Examiner		Date Considered
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		
<p>*1 = Copy not submitted because it was submitted in prior application SN __/____, filed _____, 20____, relied on under 35 USC §120.</p> <p>*2 = Copy not submitted because it was submitted in prior application SN __/____, filed _____, 20____, relied on under 35 USC §120.</p>		